REG - Argent Biopharma Ltd - PDMR Notification

Argent BioPharmaAnnouncement

30/04/2024 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd6689Ma&default-theme=true

RNS Number : 6689M  Argent Biopharma Limited  30 April 2024

30 April 2024

 

Argent BioPharma Ltd

 

PDMR Notification

 

Argent BioPharma Ltd (Argent BioPharma, RGT or the Company), wishes to advise
that the following Persons Discharging Managerial Responsibilities (PDMR) were
issued a combined 68,000 unlisted options. This notification is made in
accordance the UK Market Abuse Regulations.

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 (a)  Name                                                            Amir Polak
 2    Reason for the notification

 (a)  Position                                                        Chief Pharmaceutical Development Officer

 (b)  Initial notification/amendment                                  Initial

 (c)  If amendment: reason                                            n/a

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
      Full name of entity                                             Argent BioPharma Ltd

      Legal Entity Identifier Code                                    213800HRE3FQJ6RK4H10

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; (iv) each place
      where transactions have been conducted

 (a)  Description of the financial instrument, type of instrument     Unlisted options exercisable at A$0.70 on or before 1 April 2029.
 (b)  Identification Code (ISIN)                                      AU0000326647

 (c)  Nature of transaction                                           Grant of Options over Ordinary Shares
 (d)  Currency                        Price                                                   Volume                  Total
      AUD                             0.00                                                    12,000                  N/A
      Aggregated information
      AUD                             0.00                                                    12,000                  N/A
 (e)  Date of transaction                                             26 April 2024

 (f)  Place of transaction                                            Outside a trading venue

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 (a)  Name                                                            Yair Tal
 2    Reason for the notification

 (a)  Position                                                        Chief Information Security Officer

 (b)  Initial notification/amendment                                  Initial

 (c)  If amendment: reason                                            n/a

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
      Full name of entity                                             Argent BioPharma Ltd

      Legal Entity Identifier Code                                    213800HRE3FQJ6RK4H10

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; (iv) each place
      where transactions have been conducted

 (a)  Description of the financial instrument, type of instrument     Unlisted options exercisable at A$0.70 on or before 1 April 2029.
 (b)  Identification Code (ISIN)                                      AU0000326647

 (c)  Nature of transaction                                           Grant of Options over Ordinary Shares
 (d)  Currency                        Price                                                   Volume                  Total
      AUD                             0.00                                                    8,000                   N/A
      Aggregated information
      AUD                             0.00                                                    8,000                   N/A
 (e)  Date of transaction                                             26 April 2024

 (f)  Place of transaction                                            Outside a trading venue

 

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 (a)  Name                                                            Yifat Steuer
 2    Reason for the notification

 (a)  Position                                                        Chief Operating Officer and Deputy CEO

 (b)  Initial notification/amendment                                  Initial

 (c)  If amendment: reason                                            n/a

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
      Full name of entity                                             Argent BioPharma Ltd

      Legal Entity Identifier Code                                    213800HRE3FQJ6RK4H10

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; (iv) each place
      where transactions have been conducted

 (a)  Description of the financial instrument, type of instrument     Unlisted options exercisable at A$0.70 on or before 1 April 2029.
 (b)  Identification Code (ISIN)                                      AU0000326647

 (c)  Nature of transaction                                           Grant of Options over Ordinary Shares
 (d)  Currency                        Price                                                   Volume                  Total
         AUD                          0.00                                                    15,000                  N/A
      Aggregated information
      AUD                             0.00                                                    15,000                  N/A
 (e)  Date of transaction                                             26 April 2024

 (f)  Place of transaction                                            Outside a trading venue

 

 

 1    Details of the person discharging managerial responsibilities/person closely
      associated

 (a)  Name                                                            Itay Nissim
 2    Reason for the notification

 (a)  Position                                                        Chief Supply Chain Officer

 (b)  Initial notification/amendment                                  Initial

 (c)  If amendment: reason                                            n/a

 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
      Full name of entity                                             Argent BioPharma Ltd

      Legal Entity Identifier Code                                    213800HRE3FQJ6RK4H10

 4    Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; (iv) each place
      where transactions have been conducted

 (a)  Description of the financial instrument, type of instrument     Unlisted options exercisable at A$0.70 on or before 1 April 2029.
 (b)  Identification Code (ISIN)                                      AU0000326647

 (c)  Nature of transaction                                           Grant of Options over Ordinary Shares
 (d)  Currency                        Price                                                   Volume                  Total
         AUD                          0.00                                                    12,000                  N/A
      Aggregated information
      AUD                             0.00                                                    12,000                  N/A
 (e)  Date of transaction                                             26 April 2024

 (f)  Place of transaction                                            Outside a trading venue

 

-Ends-

 

Authorised for release by the Company Secretary, for further information
please contact:

 Argent BioPharma Limited                                     Argent BioPharma Limited

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.com (mailto:info@argentbiopharma.com)   info@argentbiopharma.com (mailto:info@argentbiopharma.com)

 UK IR/PR Advisers                                            UK Brokers

 IFC Advisory                                                 Oberon Capital

 Graham Herring / Tim Metcalfe / Zach Cohen                   Aimee McCusker / Adam Pollock

 +44 203 934 6630                                             +44 203 179 5300

 argentbiopharma@investor-focus.co.uk                         aimeemccusker@oberoninvestments.com
 (mailto:argentbiopharma@investor-focus.co.uk)                (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
                                                              (mailto:adampollock@oberoninvestments.com)

 

About Argent BioPharma

Argent BioPharma purpose is to address unmet medical needs through the
pioneering integration of Nanotechnology and Multidisciplinary research
methods. Our approach heralds a transformative shift in healthcare, combining
the power of multi-targeted drug therapies with precision nanoscale delivery
to enhance treatment efficacy while reducing side effects. Central to our
ethos is making these innovative treatments accessible, ensuring they reach
those underserved by current medical solutions. As we endeavor to become
globally recognized in the life science industry, we are committed to bridging
healthcare gaps, redefining industry standards, and providing impactful
solutions and hope to communities worldwide.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHKZGFDDGLGDZM